In-vitro method for detecting and diagnosing acute coronary...

Chemistry: analytical and immunological testing – Peptide – protein or amino acid

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S811000

Reexamination Certificate

active

06830932

ABSTRACT:

BACKGROUND OF THE INVENTION
The invention relates to an in vitro method of recognizing and diagnosing acute coronary syndroms, especially an acute myocardial infarction (AMI) in humans. Acute coronary syndroms comprise the syndroms of acute myocardial infarction and instable angina pectoris which are defined, respectively, by the WHO classification of AMI and the Braunwald classification of instable angina pectoris (Gillum R. F. et al. 1984, Am Hart J 108: 150-158; Braunwald E. et al. 1994, Circulation 90: 613-622). Acute coronary syndroms are a complex of diseases which occur frequently and often threaten life. An early, certain diagnosis and therapy may be decisive for the patient's survival. That is true particularly of an acute myocardial infarction in which case delayed proper diagnosis and late therapy may have serious consequences for the patient. There are such diagnostic measures of myocardial infarctions as the electrocardiogram and the determination of various laboratory markers. With a majority of patients, the sensitivity of the electrocardiogram and of the known laboratory markers is insufficient for diagnosis in the early phase of a myocardial infarction. As regards changes typical of an infarction reflected in the ECG (ST deflections), the sensitivity is 46% (Rude, R. E. et al. 1983, Am J Cardio 52: 936-942). The sensitivity of the laboratory markers creatine kinase (CK) activity, CK-MB activity, CK-MB mass, CK-MB isoforms, of myoglobin, and cardial troponins lies between 11-29% during the first two hours after the onset of pain (Mair, J. et al. Mitteilungen der Deutschen Gesellschaft für klinische Chemie 25: 1-6). The limited diagnostic usefulness of the known methods during the early phase of an acute myocardial infarction causes a number of clinical problems, such as the risk of erroneous diagnoses, carrying out treatments not indicated, and delaying life-saving therapies.
In the case of instable angina pectoris, patients at risk can be recognized with relative certainty by determining the cardial troponins. Due to the slow release kinetics, however, here too false negative findings are arrived at during the early phase. That is a problem because the prognosis of these patients may be about as bad as that of AMI patients and they need quick purposive antiischemic therapy. Considerable demand thus exists for methods which permit reliable, early recognition of acute coronary syndroms, particularly of an acute myocardial infarction.
SUMMARY OF THE INVENTION
It is, therefore, the object of the invention to indicate a method which allows early recognition of acute coronary syndroms, thus improving diagnosis and therapy of the stricken patients.
This object is met by a method comprising the features recited in claim
1
. With the method according to the invention of recognizing and diagonising acute coronary syndroms, especially an acute myocardial infarction, the content of choline, choline and/or trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline is determined and evaluated in body fluids or component parts of the body withdrawn from a patient.
Choline, choline and/or trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline are molecules of the lipid meta-bolism and will be referred below in summary as “CCTD”. CCTD have the following chemical formulae:
R1 and R2 represent certain chemical substituents characterizing a group of substances comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline. Plasmalogens and lysoplasmenyl choline contain an alkenyl group in these molecule parts.
Formula 1 indicates that choline represents [2-hydroxyethyl] trimethyl ammonium together with its counter ion. Formula 2 gives the general chemical formula of choline derivatives, and formula 3 presents the general formula of trimethyl ammonium derivatives, such as phosphoryl choline, as well as of plasmalogens, such as plasmenyl choline and lysoplasmenyl. The negative charge may be in the same molecule or in a counter ion. The majority of the CCTD either are component parts of phospholipids which in turn represent elements of biological membranes or are closely related to the phospholipid metabolism. Cardiac muscle cells are particularly rich in plasmenyl cholines which represent choline-containing phospholipids having a characteristic alkenyl group in the molecule. Plasmenyl cholines, furthermore, are component parts of membranes of the mitochondria which account for a considerable part of the myocardial mass. Results obtained by the applicants show that the activation of various myocardial phospholipases in the early phase of the acute myocardial infarction as well as disturbances of the lipid metabolism upon severe myocardial ischemia bring about a distinct release of choline, choline derivatives, and of the chemically related trimethyl ammonium derivatives, such as phosphoryl choline, plasmalogens, or lysoplasmenyl choline, thereby provoking an increase in concentration of CCTD in certain body fluids and component parts of the body. The extent of participation of non-myocyte elements, including endothelium cells and smooth vascular muscle cells is not known. The chemical relationship existing between choline, choline derivatives, and trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline as well as their similar behavior in pathophysiological processes, i. e. the very early release from the heart by ischemic membrane destruction are the reason for looking at them together, as CCTD.
Possible differences between the various CCTD stand back from the overwhelming common characteristic of very quick myocardial release in the event of acute coronary syndroms. This is all the more so considering the fact that the common characteristic mentioned is decisive for the essential feature of the method according to the invention in early diagnosis during the first few hours following the onset of pain.
Diagnostic utilization of the release of choline, choline derivatives, and trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline for recognition of acute coronary syndroms and acute myocardial infarction in humans has not been described as yet. The only thing known so far is that in experimental test arrangements in the early phase of myocardial ischemia a rise is observed of lysophosphoglycerides (e.g. lysophosphatidyl choline) in the myocardium and in venous as well as lymphatic effluvia (Corr, P. B. et al. 1987, J Mol Cell Cardiol 19: 34-53; Snyder, D. W. 1981, Am J Physiol 241: H700-H707; Akita, H. et al. 1986, J Clin Invest 78: 271-280). None of the publications applied a method of evaluating the content of choline, choline derivatives, and trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline in body fluids for diagnosing an acute coronary syndrom or an acute myocardial infarction in humans. The background of the publications cited, rather, is the observation that lysophosphatidyl choline apparently has proarrhythmic effects and that drugs having an anti-lysophosphatidyl choline effect possibly might be useful remedies.
The invention relates to a method of determining choline, choline and/or trimethyl ammonium derivatives, such as phosphoryl choline, plasmalogens, and lysoplasmenyl choline and/or certain reaction products for early diagnosis of acute coronary syndroms. A distinction must be made between non-inventive diacyl phosphatidyl cholines and inventive plasmenyl cholines. In the same manner, the non-inventive lysophosphatidyl cholines having an acyl group in the molecule must be distinguished from the inventive lysoplasmenyl cholines which have an alkenyl group in the molecule. Unspecific methods of determination which do not distinguish the substances according to the invention from other phospholip

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

In-vitro method for detecting and diagnosing acute coronary... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with In-vitro method for detecting and diagnosing acute coronary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In-vitro method for detecting and diagnosing acute coronary... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3299313

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.